论文部分内容阅读
目的通过研究肾细胞癌假包膜特性来评价和分析保留肾单位手术对较小的Xp11.2易位/TFE3基因融合相关性肾癌(以下简称为Xp11.2易位性肾癌)的治疗效果。方法回顾性地研究南京鼓楼医院从2007至2015年32例肾透明细胞癌患者和27例经FISH技术确诊为Xp11.2易位性肾癌患者临床及术后随访的资料,分析这两种肾细胞癌亚型假包膜和其他的临床病理学特征以及采用肾根治性切除术和肾肿瘤剜除术后患者的生存率。结果 XP11.2异位性肾癌假包膜发生率(19/27,70.4%)低于肾透明细胞癌假包膜发生率(32/32,100%)(P=0.001),但是假包膜完整性相当(13/19,68.4%vs.23/32,71.9%,P=1.000)。8位通过肾肿瘤剜除术治疗的小型XP11.2异位性肾癌患者术后恢复良好。结论大多数Xp11.2易位性肾癌都有假包膜,而且完整性和肾透明细胞癌相当,用保留肾单位手术治疗拥有完整假包膜的小型XP11.2异位性肾癌效果比较良好。
Objective To evaluate and analyze the treatment of renal cell carcinoma with small Xp11.2 translocation / TFE3 gene fusion associated renal cell carcinoma (hereinafter referred to as Xp11.2 translocation renal cell carcinoma) by studying the pseudocapsule characteristics of renal cell carcinoma effect. Methods The clinical and postoperative follow-up data of 32 patients with renal clear cell carcinoma from 2007 to 2015 and 27 patients with Xp11.2 translocation renal cell carcinoma confirmed by FISH were retrospectively studied. Subtype pseudocapsules of the cell carcinoma and other clinicopathological features as well as survival rates in patients undergoing radical nephrectomy and nephrectomy. Results The incidence of pseudophakia of XP11.2 atopic renal cell carcinoma (19/27, 70.4%) was lower than that of clear cell carcinoma of renal cell carcinoma (32/32, 100%) (P = 0.001) Sex was comparable (13/19, 68.4% vs. 23/32, 71.9%, P = 1.000). Eight patients with XP11.2 atopic renal cell carcinoma who had undergone nephrectomy had a good postoperative recovery. CONCLUSIONS Most Xp11.2 translocations have pseudocapsules with renal cell carcinoma, and their integrity is comparable to that of clear cell renal cell carcinoma. Comparison of the efficacy of nephron-preserving small XP11.2 atopic renal cell carcinoma with complete pseudocapsule good.